BioInvent International (BINV) KOL event summary

Introduction and agenda

• Event featured leading experts discussing advances in hematology, focusing on follicular lymphoma (FL) and cutaneous T-cell lymphoma (CTCL), with presentations on BI-1206 and BI-1808, including new clinical data and Q&A sessions.

• Agenda included overviews of treatment landscapes, unmet needs, clinical updates, commercial perspectives, and future development plans.

KOL background and credentials

• Guilherme Perini, São Paulo Hospital, Brazil, and Stefan K. Barta, University of Pennsylvania, are leading experts in lymphoma and immunotherapy clinical trials.

Market insights and analysis

• FL is a large, recurring market with 60,000 treated patients in US/EU and ~28,500 new cases annually; chemo-free regimens and new agents are improving outcomes but raise toxicity and access concerns.

• CTCL is rare, chronic, and relapsing, with ~96% relapse rate and high unmet need for durable, tolerable therapies; current options have significant limitations.

• Immuno-oncology market projected at $168bn with 14% CAGR, but faces bottlenecks like immunosuppressive microenvironment and tumor heterogeneity.

• Market research indicates strong commercial opportunities for BI-1206 and BI-1808, with recurring revenue potential due to chronic, relapsing nature of diseases.